Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLP-1RA for Cardiac Autonomic Neuropathy in Type 2 Diabetes
NCT07558863Phase 4Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2026
- Primary completion
- Mar 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of semaglutide and polyethylene glycol loxenatide in diabetic cardiac autonomic neuropathy (CAN) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Heart Rate Variability at 12 weeks. Started Apr 2026; status: recruiting.
02
Drugs
semaglutidepolyethylene glycol loxenatide
03
Conditions
diabetic cardiac autonomic neuropathy (CAN)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07558863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07558863.